{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-024707","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2026-05-21T10:04:26+00:00","discovered_at":"2026-05-21T10:05:01.200297+00:00","generated_at":"2026-05-21T10:05:42.625895+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR","bullets":["All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).","CR rate now 95% (19 of 20 patients) in Phase 2 NEXICART-2; no relapses observed in patients reaching CR.","All CRs reached within one year of follow-up post-dosing; median time to initial response was 7 days.","Phase 3 trial in newly diagnosed AL Amyloidosis planned to start in first half of 2027.","Next NEXICART-2 data update expected late September 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-024707","json":"https://secwatch.observer/filing/0001493152-26-024707.json","markdown":"https://secwatch.observer/filing/0001493152-26-024707.md","text":"https://secwatch.observer/filing/0001493152-26-024707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/0001493152-26-024707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T10:05:42.625895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}